Caris Life Sciences Inc. Common Stock (CAI)

About CAI

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ w…

Sector

Health Care

Industry

Medical Specialities

Employees

1,846

Website

www.carislifesciences.com/

Fundamentals

1-day range

$25.47$26.75

Market cap

$4.61B

P/E (trailing)

59.62

P/E (forward)

67.83

EPS (trailing)

$0.37

Dividend yield

—

Beta

0.44

Avg. volume

4.09M

Forecasts

12 analyst ratings

Caris Life Sciences Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• CAI

  Caris Life Sciences Inc. Common Stock

  $25.64

  ▼ 2.81%
  Market cap $4.61BP/E 59.62
  $14.19$39.18
• CELC

  Celcuity Inc. Common Stock

  $88.46

  ▼ 5.13%
  Market cap $4.28BP/E —
  $44.42$151.02
• VCYT

  Veracyte Inc. Common Stock

  $43.36

  ▼ 4.19%
  Market cap $3.58BP/E 29.24
  $28.25$60.91
• ALHC

  Alignment Healthcare Inc. Common Stock

  $13.62

  ▲ 0.44%
  Market cap $3.02BP/E 68.60
  $12.7$25.12
• GRAL

  GRAIL Inc. Common Stock

  $79.94

  ▼ 3.10%
  Market cap $3.02BP/E —
  $30.82$118.84
• BLLN

  BillionToOne Inc. Class A Common Stock

  $93.27

  ▼ 1.98%
  Market cap $6.32BP/E 117.67
  $61.96$150.44
• CDNA

  CareDx Inc. Common Stock

  $49.73

  ▼ 5.02%
  Market cap $2.48BP/E 22.08
  $12.37$53.67

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Caris Life Sciences Announces Publication Of Study Validating An AI-Driven Approach To First-Line Treatment Selection In Pancreatic Cancer In The Journal 'npj Precision Oncology'
  benzinga · 8/27/2026
• Caris Life Sciences Announces Publication Of Study Validating An AI-Driven Approach To First-Line Treatment Selection In Pancreatic Cancer In The Journal 'npj Precision Oncology'
  Benzinga · 8/27/2026
• Nasdaq 100 Falls as Hot PCE Inflation Stirs Rate-Hike Bets: Stock Market Today
  Benzinga · 8/26/2026
• Bessent's Bond Rescue Fizzles, Walmart Craters 9%: Stock Market Today
  Benzinga · 8/20/2026
• Deere, Coinbase Global, Nordson And Other Big Stocks Moving Higher On Wednesday
  Benzinga · 8/20/2026
• Tempus AI Just Had Their Entire Strategy Validated By Moderna's Vaccine Advance
  SeekingAlpha · 8/20/2026
• Caris Life Sciences, Inc. 2026 Q2 - Results - Earnings Call Presentation
  SeekingAlpha · 8/11/2026
• What’s Next For Caris Life Sciences (CAI) After 21% Jump?
  Yahoo · 8/7/2026
• Caris Life Sciences: Guidance Raised, Valuation Still Attractive
  SeekingAlpha · 8/6/2026

• David Paul Fredrickson · August 14, 2026 · Grant

  13.2K
• Lloyd Minor · August 14, 2026 · Grant

  13.2K
• Jeff L. Vacirca · August 14, 2026 · Grant

  13.2K
• Joseph E. Gilliam · August 14, 2026 · Grant

  13.2K
• T. Danny Phillips · August 14, 2026 · Grant

  13.2K
• Peter M. Castleman · August 14, 2026 · Grant

  13.2K
• Laura I. Johansen · August 14, 2026 · Grant

  13.2K
• Jon Halbert · August 14, 2026 · Grant

  13.2K
• Jonathan Kenneth Charles Knowles · May 29, 2026 · Grant

  1.6K @ $15.62
• George Poste · May 29, 2026 · Grant

  1.6K @ $15.62
• Jon Halbert · May 15, 2026 · Buy

  68.0K @ $14.56
• Luke Thomas Power · May 15, 2026 · Tax Withholding

  9.8K @ $15.25
• Brian J. Brille · May 15, 2026 · Tax Withholding

  14.0K @ $15.25
• David Baxley Spetzler · May 15, 2026 · Tax Withholding

  13.9K @ $15.25
• John Russel Denton · May 15, 2026 · Tax Withholding

  6.0K @ $15.25

Institutional Ownership

March 31, 2026

Total shares held

150.01M

Total value held

$2.47B

Institutional holders

197